Phospho-RSK2 (Ser227) Antibody (YA156)
(Synonyms: RPS6KA3; ISPK1; MAPKAPK1B; RSK2; Ribosomal protein S6 kinase alpha-3; S6K-alpha-3; 90 kDa ribosomal protein S6 kinase 3; p90-RSK 3; p90RSK3; Insulin-stimulated protein kinase 1; ISPK-1; MAP kinase-activated protein kinase 1b; MAPK-activated)Phospho-RSK2 (Ser227) Antibody (YA156) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-RSK2 (Ser227).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IP
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol and 0.05% BSA. Preservative: 0.01% Sodium azide
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IP
IP: Immunoprecipitation
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:20 |
Product Details
Phospho-RSK2 (Ser227) Antibody (YA156) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-RSK2 (Ser227).
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 84 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 84 kDa
Entrez Gene: 6197 Human ; 110651 Mouse ; 501560 Rat
SwissProt: P51812 Human ; P18654 Mouse ;
OMIM: 303600 Human
Synthetic phosphopeptide corresponding to residues surrounding Ser227 of Human Rsk 2/MAPKAP Kinase 1b.The exact sequence is proprietary to MCE.
Endogenous
affinity purified
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol and 0.05% BSA. Preservative: 0.01% Sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
RSK2 (ribosomal S6 kinase 2, RPS6KA3) is a widely expressed serine/threonine kinase of the p90RSK family that functions downstream of ERK1/2 and phosphoinositide-dependent kinase 1, positioning it as a critical effector of MAPK signaling that regulates cell survival, proliferation, and transcriptional responses[1][2]. RSK2 integrates extracellular growth-factor signals into intracellular phosphorylation events and contributes to the control of cell-cycle progression and transformation-associated programs through phosphorylation of downstream substrates[1][3]. Mechanistically, RSK2 participates in RAS-MAPK pathway regulation and influences phosphorylation of signaling and transcriptional regulators, thereby affecting cellular growth and adaptive responses[2][4]. In disease-relevant models, genetic deletion or knockdown of RSK2 suppresses cell proliferation, induces G1-phase accumulation, and reduces oncogenic transformation, whereas increased RSK2 activity promotes tumor-promoter-induced cell transformation and cancer-related phenotypes[1][5]. RSK2 is also clinically significant because loss-of-function mutations in RPS6KA3 cause Coffin-Lowry syndrome, linking RSK2-dependent signaling to neurodevelopmental and skeletal abnormalities[6][7]. Compared with related RSK isoforms, RSK2 has been identified as a specific binding partner of SPRED2, revealing isoform-selective regulation within the RAS-MAPK network and highlighting functional distinctions that are not shared uniformly across the RSK family[2]. For experimental applications, pharmacological inhibitors including kaempferol and the RSK inhibitor BI-D1870 have been used to suppress RSK-dependent signaling, making RSK2 a valuable target for mechanistic studies of MAPK-driven proliferation, transformation, and therapeutic intervention strategies[1][4].
-
Subcellular Localization
Nucleus; Cytoplasm
-
Expression
Tissue_specificity:It is expressed in a variety of tissues, with the highest concentration in skeletal muscle. -
Subunit
Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in quiescent cells. Transiently dissociates following mitogenic stimulation (By similarity). Interacts with NFATC4, ETV1/ER81 and FGFR1
-
SwissProt ID
-
Synonyms
RPS6KA3; ISPK1; MAPKAPK1B; RSK2; Ribosomal protein S6 kinase alpha-3; S6K-alpha-3; 90 kDa ribosomal protein S6 kinase 3; p90-RSK 3; p90RSK3; Insulin-stimulated protein kinase 1; ISPK-1; MAP kinase-activated protein kinase 1b; MAPK-activated
-
Research Field
Signal Transduction
Documentation
[1]. Cho YY, et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res. 2007 Sep 1;67(17):8104-12. [Content Brief]
[2]. Lopez J, et al. The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling. J Biol Chem. 2023 Jun;299(6):104789. [Content Brief]
[3]. Spirrison AN, et al. RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data. Expert Opin Ther Targets. 2024 Dec;28(12):1047-1059. [Content Brief]
[4]. Wright EB, et al. Therapeutic targeting of p90 ribosomal S6 kinase. Front Cell Dev Biol. 2023 Dec 19;11:1297292. [Content Brief]
[5]. Cho YY, et al. RSK2 as a key regulator in human skin cancer. Carcinogenesis. 2012 Dec;33(12):2529-37. [Content Brief]
[6]. RSK2 gene information from NCBI.
[7]. Rogers RC, et al. RPS6KA3-Related Intellectual Disability. 2002 Jul 16 [updated 2023 Mar 16]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. [Content Brief]
Powered by Bioz
